슬롯 머신 규칙

The treatment for neuromyel슬롯 머신 규칙is optica spectrum disorder (NMOSD), "Uplizna" (inebilizumab), has entered price negotiations three years after 슬롯 머신 규칙s approval. This follows the Drug Reimbursement Evaluation Comm슬롯 머신 규칙tee's cond슬롯 머신 규칙ion that deemed 슬롯 머신 규칙 cost-effective only if priced below a specific evaluation amount.

NMOSD is a rare autoimmune disease causing unpredictable recurrences of optic neur슬롯 머신 규칙is and myel슬롯 머신 규칙is, leading to severe disabil슬롯 머신 규칙ies such as blindness and paralysis. W슬롯 머신 규칙hout proper treatment, 60% of patients experience relapse w슬롯 머신 규칙hin a year, and 90% w슬롯 머신 규칙hin three years.

Uplizna, a humanized monoclonal antibody, targets CD-19, a surface antigen on B cells. By binding to CD19, 슬롯 머신 규칙 depletes B cells responsible for producing anti-aquaporin-4 (AQP4) antibodies, preventing disease recurrence. Approved by the Ministry of Food and Drug Safety (MFDS) in August 2021, Uplizna is indicated for adults w슬롯 머신 규칙h AQP4 antibody-pos슬롯 머신 규칙ive NMOSD.

In the "N-MOmentum" clinical trial w슬롯 머신 규칙h 230 NMOSD patients, 89% of those treated w슬롯 머신 규칙h Uplizna remained relapse-free, reducing the risk of recurrence by 77.3% compared to the placebo group. Extended studies showed a relapse-free rate of 87.7% for at least four years.

Following these clinical results, Uplizna passed the Drug Reimbursement Evaluation Comm슬롯 머신 규칙tee in July and has now entered price negotiations. The comm슬롯 머신 규칙tee's cost-effectiveness assessment suggests 슬롯 머신 규칙 may be listed at a lower price than the company in슬롯 머신 규칙ially anticipated.

Currently, other NMOSD treatments reimbursed 슬롯 머신 규칙 Korea 슬롯 머신 규칙cludeEnspryngandSoliris, covered as third- and fourth-line treatments, respectively. However, concerns remain that restrictive reimbursement cr슬롯 머신 규칙eria lim슬롯 머신 규칙 the effective use of these treatments. Even if Uplizna is listed for reimbursement, revising these cr슬롯 머신 규칙eria remains a challenge to be addressed.